Similarly, in NRAS-mutant melanoma cells treated with combination MEK and CDK4/6 inhibitors, scRNA-seq revealed distinct cell clusters reflecting heterogeneity in transcriptional response to treatment, and differences in response was postulated to cause outgrowth of intrinsically resistant melanoma subpopulations.53 The gene discussed is NRAS; the disease is melanoma.